- Home
- SITC vs GHRS Comparison
SITC vs GHRS Comparison
Compare SITC & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SITC
- GHRS
- Stock Information
- Founded
- SITC 1965
- GHRS 2018
- Country
- SITC United States
- GHRS Ireland
- Employees
- SITC N/A
- GHRS N/A
- Industry
- SITC Real Estate Investment Trusts
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- SITC Real Estate
- GHRS Health Care
- Exchange
- SITC Nasdaq
- GHRS Nasdaq
- Market Cap
- SITC 786.5M
- GHRS 868.7M
- IPO Year
- SITC 1993
- GHRS 2021
- Fundamental
- Price
- SITC $13.02
- GHRS $12.57
- Analyst Decision
- SITC Hold
- GHRS Strong Buy
- Analyst Count
- SITC 8
- GHRS 7
- Target Price
- SITC $35.61
- GHRS $30.86
- AVG Volume (30 Days)
- SITC 1.2M
- GHRS 264.8K
- Earning Date
- SITC 04-29-2025
- GHRS 05-02-2025
- Dividend Yield
- SITC 3.97%
- GHRS N/A
- EPS Growth
- SITC 101.37
- GHRS N/A
- EPS
- SITC 9.77
- GHRS N/A
- Revenue
- SITC $278,932,000.00
- GHRS N/A
- Revenue This Year
- SITC N/A
- GHRS N/A
- Revenue Next Year
- SITC N/A
- GHRS N/A
- P/E Ratio
- SITC $1.36
- GHRS N/A
- Revenue Growth
- SITC N/A
- GHRS N/A
- 52 Week Low
- SITC $12.58
- GHRS $6.00
- 52 Week High
- SITC $64.44
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- SITC 39.25
- GHRS 61.33
- Support Level
- SITC $12.60
- GHRS $10.20
- Resistance Level
- SITC $13.27
- GHRS $11.75
- Average True Range (ATR)
- SITC 0.31
- GHRS 0.91
- MACD
- SITC 0.07
- GHRS 0.23
- Stochastic Oscillator
- SITC 50.00
- GHRS 93.57
About SITC SITE Centers Corp.
SITE Centers Corp is a United States-based self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing and managing shopping centers.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.